Theorem Clinical Research

Drug Sponsors

Salix Pharmaceuticals, Cosmo Technologies terminate merger agreement

Friday, October 3, 2014 10:50 AM

Salix Pharmaceuticals, based in Raleigh, N.C., and Lainate, Italy-based Cosmo Pharmaceuticals have agreed to terminate their previously-announced merger agreement pursuant to which Salix would have combined with, and become a wholly-owned subsidiary of, Cosmo Technologies, a subsidiary of Cosmo Pharmaceuticals. Effective immediately, Salix will make a $25 million payment to Cosmo.

More... »


BioNTech, Ganymed Pharmaceuticals open research headquarters in Germany

Thursday, October 2, 2014 02:14 PM

BioNTech and Ganymed Pharmaceuticals, two German biotechology companies, have opened a 108,000-square-foot headquarters and research facility. The new facility brings together 300 employees and is located near academic institutions, hospitals and cancer research institutions.

More... »


Baxter to form new innovation and R&D center for biopharmaceuticals

Wednesday, October 1, 2014 01:26 PM

Baxter International plans to form a new global innovation and R&D center in Cambridge, Mass., for Baxter's biopharmaceuticals business, which is expected to become a separate, independent global company known as Baxalta in mid-2015.

More... »

Johnson & Johnson to acquire Alios BioPharma

Wednesday, October 1, 2014 01:04 PM

Johnson & Johnson has announced a definitive agreement to acquire Alios BioPharma, a San Francisco-based, privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for approximately $1.75 billion in cash.

More... »

Novo Nordisk establishes obesity research unit in Seattle

Tuesday, September 30, 2014 08:00 AM

Novo Nordisk will establish a new obesity research unit in Seattle, Wash. The new unit is a result of Novo Nordisk's increasing focus on obesity. Its main task will be to identify novel approaches and targets for obesity treatments, while increasing the scientific understanding of existing obesity targets.

More... »

Lumara Health to be acquired in two separate transactions

Monday, September 29, 2014 01:26 PM

Lumara Health, a Missouri-based specialty pharmaceutical company, has entered into two separate definitive agreements for the sale of its maternal health business and, separately, the sale of its women's healthcare assets.

More... »

Daiichi Sankyo to acquire Ambit Biosciences for $410M

Monday, September 29, 2014 01:12 PM

Daiichi Sankyo, a Japan-based pharmaceutical, will acquire all outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer, followed by a merger with a subsidiary of Daiichi Sankyo, or approximately $315 million on a fully diluted basis.

More... »

Cancer Core Europe consortium launches

Friday, September 26, 2014 03:15 PM

Cancer Core Europe—a consortium to address the cancer care/research continuum challenge, has launched. Its members are Gustave Roussy Cancer Campus Grand Paris; Cambridge Cancer Center, based in the U.K.; Karolinska Institute, of Stockholm, Sweden; the Netherlands Cancer InstituteVall d'Hebron Institute of Oncology (VHIO), of Barcelona, Spain; and the German Cancer Research Center (DKFZ) and its National Center for Tumor Diseases (NCT).

More... »

Bristol-Myers Squibb to build state-of-the-art campus in New Jersey

Thursday, September 25, 2014 12:52 PM

Bristol-Myers Squibb plans to build a 650,000-square-foot office building on company-owned land in Lawrenceville, N.J. Construction is expected to begin in the fall and the new facility is expected to open by the end of 2016.

More... »

Acorda Therapeutics to acquire Civitas Therapeutics

Thursday, September 25, 2014 12:48 PM

Acorda Therapeutics, a biotechnology company based in Ardsley, N.Y., has entered into an agreement to acquire Civitas Therapeutics, a Chelsea, Mass.-based, privately held biopharmaceutical company, for $525 million in cash. Acorda will obtain worldwide rights to CVT-301, a phase III treatment candidate for OFF episodes of Parkinson’s disease (PD). The acquisition also includes rights to Civitas’ proprietary ARCUS pulmonary delivery technology and manufacturing facility with commercial-scale capabilities.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 27

NIH’s I-Corps boot camp aims to transform researchers into better businesspeople before they launch products

Covance, Frenova form partnership to share patient databases, find effective treatments for renal disease

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs